Article information
Abstract
Cytomegalovirus infection remains a serious threat to solid transplant recipients. Despite advances in this field, there are still difficulties in the diagnosis of the disease and there are questions about the best and most cost-effective strategy to prevent infection and its direct and indirect consequences in the short and long term. All these points are discussed and updated in this chapter.
Keywords:
Cytomegalovirus
Disease
Infection
Solid organ
Transplantation
Resumen
La infección por citomegalovirus sigue siendo una amenaza grave para los receptores de trasplante de órgano sólido. A pesar de los avances en este campo existen aún dificultades en el diagnóstico de esta enfermedad y dudas sobre cuál es la estrategia mejor y más coste-efectiva para prevenir la infección y sus consecuencias directas e indirectas a corto y largo plazo. Todos estos puntos se discuten y se actualizan en este capítulo.
Palabras clave:
Citomegalovirus
Enfermedad
Infección
Órgano sólido
Trasplante
Full text is only aviable in PDF
References
[1.]
T. Crough, R. Khanna.
Immunobiology of human cytomegalovirus: from bench to benchside.
Clin Microbiol Rev, 22 (2009), pp. 76-98
[2.]
V.C. Emery, C.A. Sabin, A.V. Cope, D. Gor, A.F. Hassan-Walker, P.D. Griffiths.
Application of viral-load kinetics to identify patients who develop Cytomegalovirus disease after transplantation.
Lancet, 355 (2000), pp. 2032-2036
[3.]
G.P. Westall, A. Michaelides, T.J. Williams, G.I. Snell, T.C. Kotsimbos.
Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: a longitudinal study of lung transplant recipients.
J Infect Dis, 190 (2004), pp. 1076-1083
[4.]
W. Van der Bij, R. Torensma, W.J. Van Son, J. Anema, J. Schirm, A.M. Tegzess.
The TH. l: Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leukocytes.
J Med Virol, 25 (1988), pp. 179-188
[5.]
C. Solano, I. Muñoz, A. Gutiérrez, A. Farga, F. Prósper, J. García-Conde, et al.
Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation.
J Clin Microbiol, 39 (2001), pp. 3938-3941
[6.]
E.Y. Jang, S.Y. Park, E.J. Lee, E.H. Song, Y.P. Chong, S.O. Lee, et al.
Diagnostic performance of the cytomegalovirus (CMV) antigenemia assay in patients with CMV gastrointestinal disease.
Clin Infect Dis, 48 (2009), pp. 121-124
[7.]
G. Gerna, D. Lilleri, M. Furione, F. Baldanti.
Management of human cytomegalovirus infection in transplantation: validation of virologic cut-offs for preemptive therapy and immunological cut-offs for protection.
New Microbiol, 34 (2011), pp. 229-254
[8.]
C. Gimeno, C. Solano, J.C. Latorre, J.C. Hernández-Boluda, M.A. Clari, M.J. Remigia, et al.
Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients.
J Clin Microbiol, 46 (2008), pp. 3311-3318
[9.]
M.J. Espy, J.R. Uhl, M. Sloan, S.P. Buckwalter, M.F. Jones, E.A. Vetter, et al.
Real-time PCR in clinical microbiology: Applications for routine laboratory testing.
Clin Microbiol Rev, 19 (2006), pp. 165-256
[10.]
D. Bravo, M.A. Clari, E. Costa, B. Muñoz-Cobo, C. Solano, M. José Remigia, et al.
Comparative evaluation of three automated systems for DNA Extraction in Conjunction with Three Commercially Available Real-Time PCR Assays for Quantitation of Plasma Cytomegalovirus DNAemia in Allogeneic Stem Cell Transplant Recipients.
J Clin Microbiol, 49 (2011), pp. 2899-2904
[11.]
P. Ljungman, P. Griffiths, C. Paya.
Definitions of HCMV infection and disease in transplant recipients.
Clin Infect Dis, 34 (2002), pp. 1094-1097
[12.]
C. Gilbert, G. Boivin.
Human cytomegalovirus resistance to antiviral drugs.
Antimicrob Agents Chemother, 49 (2005), pp. 873-883
[13.]
J.A. Fishman, V. Emery, R. Freeman, M. Pascual, L. Rostaing, H.J. Schlitt, et al.
Cytomegalovirus in transplantation-challenging the status quo.
Clin Transplant, 21 (2007), pp. 149-158
[14.]
R. San Juan, J.M. Aguado, C. Lumbreras, J. Fortún, P. Muñoz, J. Gavaldà, et al.
Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation.
Clin Infect Dis, 47 (2008), pp. 875-882
[15.]
F. López-Medrano, B. Rueda, M. Lizasoain, R. San Juan, D. Folgueira, A. Andrés, et al.
Preemptive therapy is not adequate for prevention of cytomegalovirus disease in pancreas-kidney transplant recipients.
Transpl Infect Dis, 11 (2009), pp. 400-404
[16.]
A.A. Boudreault, H. Xie, R.M. Rakita, J.D. Scott, C.L. Davis, M. Boeckh, et al.
Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis.
Transpl Infect Dis, 13 (2011), pp. 244-249
[17.]
J.K. Preiksaitis, J. Sandhu, M. Strautman.
The risk of transfusion-acquired CMV infection in seronegative solid-organ transplant recipients receiving non-WBC-reduced blood components not screened for CMV antibody (1984 to 1996): experience at a single Canadian center.
Transfusion, 42 (2002), pp. 396-402
[18.]
J.P. Fryer.
Intestinal transplantation: current status.
Gastroenterol Clin North Am, 36 (2007), pp. 145-159
[19.]
V. Monforte, C. López, F. Santos, F. Zurbano, M. De la Torre, A. Solé, et al.
A multicenter study of valganciclovir prophylaxis up to day 120 in CMV-seropositive lung transplant recipients.
Am J Transplant, 9 (2009), pp. 1134-1141
[20.]
C. Lumbreras, J.R. Otero, J.M. Aguado, M. Lizasoaín, R. Gómez, I. García, et al.
Prospective study of cytomegalovirus infection in liver transplant recipients.
Med Clin (Barc), 99 (1992), pp. 401-405
[21.]
I.G. Sia, R. Patel.
New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients.
Clin Microbiol Rev, 13 (2000), pp. 83-121
[22.]
Y. Baez, F. Giron, A. Nino-Murcia, J. Rodríguez, S. Salcedo.
Experience with Alemtuzumab (Campath-1H) as induction agent in renal transplantation followed by steroid-free immunosuppression.
Transplant Proc, 40 (2008), pp. 697-699
[23.]
C.G. Ter Meulen, J.F. Wetzels, L.B. Hilbrands.
The influence of mycophenolate mofetil on the incidence and severity of primary cytomegalovirus infections and disease after renal transplantation.
Nephrol Dial Transplant, 15 (2000), pp. 711-714
[24.]
M. Giral, J.M. Nguyen, P. Daguin, M. Hourmant, D. Cantarovich, J. Dantal, et al.
Mycophenolate mofetil does not modify the incidence of cytomegalovirus (CMV) disease after kidney transplantation but prevents CMV-induced chronic graft dysfunction.
J Am Soc Nephrol, 12 (2001), pp. 1758-1763
[25.]
J.A. DesJardin, E. Cho, S. Supran, L. Gibbons, B.G. Werner, D.R. Snydman.
Association of human herpesvirus 6 reactivation with severe cytomegalovirus-associated disease in orthotopic liver transplant recipients.
Clin Infect Dis, 33 (2001), pp. 1358-1362
[26.]
R.J. Stratta, C. Pietrangeli, G.M. Baillie.
Defining the risks for cytomegalovirus infection and disease after solid organ transplantation.
Pharmacotherapy, 30 (2010), pp. 144-157
[27.]
S. Sagedal, K.P. Nordal, A. Hartmann, M. Degré, E. Holter, A. Foss, et al.
A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients.
Transplantation, 70 (2000), pp. 1166-1174
[28.]
C. Cervera, F. Lozano, N. Saval, I. Gimferrer, A. Ibañez, B. Suárez, et al.
The influence of innate immunity gene receptors polymorphisms in renal transplant infections.
Transplantation, 83 (2007), pp. 1493-1500
[29.]
O. Manuel, M. Pascual, M. Trendelenburg, P.R. Meylan.
Association between mannosebinding lectin deficiency and cytomegalovirus infection after kidney transplantation.
Transplantation, 83 (2007), pp. 359-362
[30.]
A.C. Kalil, J. Levitsky, E. Lyden, J. Stoner, A.G. Freifeld.
Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients.
Ann Intern Med, 143 (2005), pp. 870-880
[31.]
D.J. Winston, R.W. Busuttil.
Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
Transplantation, 75 (2003), pp. 229-233
[32.]
D. Lowance, H.H. Neumayer, C.M. Legendre, J.P. Squifflet, J. Kovarik, P.J. Brennan, et al.
Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
N Engl J Med, 340 (1999), pp. 1462-1470
[33.]
C. Paya, A. Humar, E. Dominguez, K. Washburn, E. Blumberg, B. Alexander, et al.
Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients.
Am J Transplant, 4 (2004), pp. 611-620
[34.]
C.N. Kotton, D. Kumar, A.M. Caliendo, A. Asberg, S. Chou, D.R. Snydman, et al.
International consensus guidelines on the management of cytomegalovirus in solid organ transplantation.
Transplantation, 89 (2010), pp. 779-795
[35.]
J. Torre-Cisneros, M.C. Fariñas, J.J. Castón, J.M. Aguado, S. Cantisán, J. Carratalá, et al.
GESITRA-SEIMC/REIPI Recommendations for the management of cytomegalovirus infection in solid-organ transplant patients.
Enferm Infecc Microbiol Clin, (2011),
[36.]
H.A. Valantine, H. Luikart, R. Doyle, J. Theodore, S. Hunt, P. Oyer, et al.
Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone.
Transplantation, 72 (2001), pp. 1647-1652
[37.]
A. Asberg, A. Humar, H. Rollag, A.G. Jardine, H. Mouas, M.D. Pescovitz, et al.
Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients.
Am J Transplant, 7 (2007), pp. 2106-2113
[38.]
A. Asberg, A. Humar, A.G. Jardine, H. Rollag, M.D. Pescovitz, H. Mouas, et al.
Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients.
Am J Transplant, 9 (2009), pp. 1205-1213
[39.]
V.C. Emery, P.D. Griffiths.
Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy.
Proc Natl Acad Sci U S A, 97 (2000), pp. 8039-8044
[40.]
J.P. Sommadossi, R. Bevan, T. Ling, F. Lee, B. Mastre, M.D. Chaplin, et al.
Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function.
Rev Infect Dis, 10 (1988), pp. S507-S514
[41.]
F. Li, K.W. Kenyon, K.A. Kirby, D.P. Fishbein, M. Boeckh, A.P. Limaye.
Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients.
Clin Infect Dis, 45 (2007), pp. 439-447
[42.]
E. Mylonakis, W.M. Kallas, J.A. Fishman.
Combination antiviral therapy for ganciclovirresistant cytomegalovirus infection in solid-organ transplant recipients.
Clin Infect Dis, 34 (2002), pp. 1337-1341
[43.]
A.J. Eid, R.R. Razonable.
New developments in the management of cytomegalovirus infection after solid organ transplantation.
Drugs, 70 (2010), pp. 965-981
[44.]
M.Y. Shapira, I.B. Resnick, S. Chou, A.U. Neumann, N.S. Lurain, T. Stamminger, et al.
Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation.
Clin Infect Dis, 46 (2008), pp. 1455-1457
[45.]
R.K. Avery, F.M. Marty, L. Strasfeld, I. Lee, A. Arrieta, S. Chou, et al.
Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients.
Transpl Infect Dis, 12 (2010), pp. 489-496
[46.]
F.M. Marty, P. Ljungman, G.A. Papanicolaou, D.J. Winston, R.F. Chemaly, L. Strasfeld, et al.
Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomized trial.
Lancet Infect Dis, 11 (2011), pp. 284-292
[47.]
H. Einsele, E. Roosnek, N. Rufer, C. Sinzger, S. Riegler, J. Loffler, et al.
Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy.
Blood, 99 (2002), pp. 3916-3922
[48.]
S.A. Plotkin, M.L. Smiley, H.M. Friedman, S.E. Starr, G.R. Fleisher, C. Wlodaver, et al.
Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants.
Lancet, 1 (1984), pp. 528-530
[49.]
R.F. Pass, C. Zhang, A. Evans, T. Simpson, W. Andrews, M.L. Huang, et al.
Vaccine prevention of maternal cytomegalovirus infection.
N Engl J Med, 360 (2009), pp. 1191-1199
Copyright © 2012. Elsevier España S.L.. All rights reserved
